Hepatocellular carcinoma
Conditions
Interventions
experimental group:TACE combined with Metronidazole
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-75 years old; (2) newly diagnosed as HCC; (3) BCLC B or C stage, without extra-hepatic metastasis or portal vein tumor thrombus; (4) Child-Pugh Class A or B; (5) ECOG score 0 or 1; (6) expected survival time > 3 months; (7) WBC >= 3 x 10^9/L; (8) PLT >= 50 x 10^9/L; (9) AST, ALT 50%; (11) TBiL < 51µmol/L; (12) be willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) with extra-hepatic metastasis or portal vein tumor thrombus; (2) with diffused tumors; (3) with the history of targeting therapies or immunotherapies; (4) with abnormal renal function; (5) with history of other tumors; (6) decompensated liver cirrhosis; (7) with central nervous system diseases; (8) with hematonosis; (9) pregnant women or breast feeding women; (10) with history of drinking alcohol within 1 week; (11) with history of taking liver enzyme inducers or liver enzyme inhibitors within 3 months; (12) with severe cardiopulmonary diseases; (13) with severe diseases of other systems; (14) rejecting to participate into this trial.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Tumor response;Progression free survival;The serum concentration of metronidazole; | — |
Primary
| Measure | Time frame |
|---|---|
| Survival rate at 1-year; | — |
Countries
China
Contacts
Public ContactLi Wei
Beijing Ditan Hospital, Capital Medical University
Outcome results
None listed